Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer-Reference-Cited by-同舟云学术

Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer

Published:2007-11-20 Issue:6 Volume:122 Page:1400-1410
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Qian Xiaozhong,Ara Gulshan,Mills Evan,LaRochelle William J.,Lichenstein Henri S.,Jeffers Michael

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference38 articles.

1. Anticancer activities of histone deacetylase inhibitors;Bolden;Nat Rev Drug Discov,2006

2. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer;Minucci;Nat Rev Cancer,2006

3. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101;Plumb;Mol Cancer Ther,2003

4. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies;Qian;Mol Cancer Ther,2006

5. Nuclear factor-κB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101;Duan;Mol Cancer Ther,2007

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential bladder cancer therapeutic delivery systems: a recent update;Expert Opinion on Drug Delivery;2024-09-11

2. Research strategies of small molecules as chemotherapeutics to overcome multiple myeloma resistance;European Journal of Medicinal Chemistry;2024-05

3. Epigenetic biomarkers;Epigenetics in Human Disease;2024

4. Complexation of histone deacetylase inhibitor belinostat to Cu(II) prevents premature metabolic inactivation in vitro and demonstrates potent anti-cancer activity in vitro and ex vivo in colon cancer;Cellular Oncology;2023-11-07

5. Anticancer clinical efficiency and stochastic mechanisms of belinostat;Biomedicine & Pharmacotherapy;2023-09